An interventional study of high-resolution PET-CT specimen imaging. in Breast Cancer, Breast Cancer Invasive and Breast Cancer in Situ, sponsored by XEOS Medical. Completed at 1 site in Belgium. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-05.
Sponsored by XEOS Medical · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 549 studies in Breast Neoplasms with a site in Belgium — 72 open to participants now, 137 under way, 64 of them phase 3. Breast Neoplasms · Belgium.
Among the 549 studies in Breast Neoplasms with a site in Belgium, this one is the 222nd largest by enrollment of the 486 interventional ones that give a count, is one of 28 that started in 2022, is one of 75 with no phase, and was the 435th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →72 of the 549 studies in Breast Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Belgium, United States, France and 5 more countries
Ages 18+
UNICANCER · Sites in Belgium, France, Greece and 4 more countries
Ages 35–45 · Women only
Hoffmann-La Roche · Sites in Belgium, United States, Argentina and 23 more countries
Ages 18+
Eli Lilly and Company · Sites in Belgium, United States, France and 4 more countries
Ages 18+ · Women only
Jessa Hospital · Sites in Belgium
Ages 18+ · Women only · Healthy volunteers
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
549 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 86 · Phase 2 187 · Phase 3 174 · Phase 4 9
First in 1987; this study’s year is marked. 28 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 206 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 166 across the 486 interventional studies, 150 across the 58 observational. Of the 383 that completed or were terminated, 189 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
339 of 549 have an industry lead sponsor. The 10 most frequent:
XEOS Medical is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
XEOS Medical has 2 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
31 of the studies in Breast Neoplasms with a site in Belgium that are under way reach primary completion within a year, 15 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07373782Phase 3Universitaire Ziekenhuizen KU LeuvenContinuous Positive Airway Pressure (CPAP) Assisted Radiotherapy in Breast Cancer | 2026-12 |
| NCT05038735Phase 3Novartis PharmaceuticalsStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | 2027-01-28 |
| NCT04208178Phase 3Novartis PharmaceuticalsStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | 2027-02-26 |
| NCT04873362Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | 2027-03-31 |
| NCT05696626Phase 3LeonaBioEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | 2027-04 |
Add all 31 to your calendar (.ics) → With an account.
Among the 549 studies in Breast Neoplasms with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Breast-conserving surgery (BCS) has become the standard-of-care for surgical management of the majority of women with early-stage breast cancer. Successful BCS entails excision of the tumor with an adequate amount of surrounding healthy breast parenchyma, such that negative resection margins are obtained. Despite efforts to obtain tumor-free margins, approximately 20-30% of women still require reoperation.
The rationale of this study is to examine the contribution of the adjunctive use of perioperative high-resolution PET-CT specimen imaging in early-stage breast cancer to the identification of all positive resection margins during breast-conserving surgery. Histopathological findings of the breast tumor specimen are applied as the gold standard.
After a successful screening phase and after informed consent is provided, the patient will enroll the study. The preparations for the BCS proceed following the routine protocol (i.e. as if the patient would not participate in the study). In addition to these standard preparations, on the day of surgery the patient will receive a study-specific injection with a low dose of a radiotracer substance (18F-FDG; 0.8 MBq/kg). Before injection, the blood sugar level will be measured by a small finger prick. If the blood sugar level is good, the radiotracer substance will be intravenously administered. The injection is given at the nuclear medicine department between 30 minutes and 3 hours before surgery. After the injection was given, the patient will be transferred to the operating theatre. The breast tumor will be removed in the same way as if the patient is not participating in the study. As soon as the tumor is excised, it will be imaged using the specimen PET-CT scanner in the operating theatre. While waiting for these 3D images, the surgeon will remove the lymph nodes, if applicable. The breast surgeon will then evaluate the 3D images of the removed breast tumor. In case of suspected positive margins, the surgeon will excise additional breast tissue to ensure that all tumor tissue is excised during this surgery. For scientific purposes only and if available, the cavity shaves and resected lymph nodes will also be imaged with the specimen PET-CT scanner. No clinical decisions that could affect further treatment will be based on this. After surgery, all excised tissues will be sent to the pathology department. This is standard routine and is also done for patients not participating in the study. A routine follow-up visit will be planned with the surgeon. During that routine visit, a staff member of the study team will ask additional study-related questions regarding possible complications. If the latter is not possible during the standard follow-up visit, a staff member of the study team will contact the patient by phone call 1-3 weeks after surgery. The study is completed after this follow-up visit or phone call.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
a minimal tumor size of 1.0 cm (in at least one dimension):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: high-resolution PET-CT specimen imaging.
A single intravenous injection of 18F-FDG (0.80 MBq/kg) is given between 30 minutes and 3 hours before tumor resection. Surgical resection of the breast tumor (= main specimen) under general anesthesia. The main specimen is imaged using the Aura 10 PET-CT Specimen Imager (XEOS Medical, Ghent, Belgium). In case of positive margins, the surgeon will perform oriented cavity shaving. The cavity shaves and lymph nodes (if any) are also imaged using the Aura 10 PET-CT Specimen Imager (for scientific purposes only). The main specimen and if applicable the cavity shaves and lymph node(s) are processed following standard-of-care routine: from tissue samples to HE-stained and IHC-stained sections. The histopathological margin status shall be reported according to the ASCO-CAP guidelines, and shall be compared to the PET-CT images of the resected specimens.
Perioperative addressing positive margins of the invasive component in IDC.
The primary effectiveness endpoint is a measure of perioperative success in addressing positive margins of the invasive component with the adjunctive use of high-resolution PET-CT specimen imaging as detected by permanent pathology in the IDC subgroup.
Time frame: Perioperative (day 0).
Perioperative addressing positive margins of the invasive component in breast cancer.
A measure of perioperative success in addressing positive margins of the invasive component with the adjunctive use of high-resolution PET-CT specimen imaging as detected by permanent pathology in: * the total study population excluding the DCIS subgroup (IDC + ILC + NAT); * the ILC subgroup; * the NAT subgroup.
Time frame: Perioperative (day 0).
Perioperative addressing any positive margin in breast cancer.
A measure of perioperative success in addressing any positive margin with the adjunctive use of high-resolution PET-CT specimen imaging as detected by permanent pathology in: * the total study population (IDC + DCIS + ILC + NAT); * the IDC subgroup; * the DCIS subgroup; * the ILC subgroup; * the NAT subgroup.
Time frame: Perioperative (day 0).
Perioperative success in obtaining final negative margins of the invasive component in breast cancer.
A measure of perioperative success in obtaining final negative margins of the invasive component as detected by permanent pathology (1) by the additional use of high-resolution PET-CT imaging and (2) by additional use of standard-of-care in: * the total study population excluding DCIS (IDC + ILC + NAT); * the IDC subgroup; * the ILC subgroup; * the NAT subgroup.
Time frame: Perioperative (day 0).
Perioperative success in obtaining final negative margins in breast cancer.
A measure of perioperative success in obtaining final negative margins (invasive and/or in situ component) as detected by permanent pathology (1) by the additional use of high-resolution PET-CT imaging and (2) by additional use of standard-of-care in: * the total study population (IDC + DCIS + ILC + NAT); * the IDC subgroup; * the DCIS subgroup; * the ILC subgroup; * the NAT subgroup.
Time frame: Perioperative (day 0).
Final positive margins of the invasive component after breast-conserving surgery.
A measure of the number of patients with final positive resection margins of the invasive component after BCS in: * the total study population excluding DCIS (IDC + ILC + NAT); * the IDC subgroup; * the ILC subgroup; * the NAT subgroup.
Time frame: Perioperative (day 0).
Final positive margins of any margin after breast-conserving surgery.
A measure of the number of patients with final positive resection margins (invasive and/or in situ component) after BCS in: * the total study population (IDC + DCIS + ILC + NAT); * the IDC subgroup; * the DCIS subgroup; * the ILC subgroup; * the NAT subgroup.
Time frame: Perioperative (day 0).
Diagnostic performance based on the invasive component of breast cancer.
Sensitivity, specificity, positive and negative predictive value, failure rate and, interobserver reproducibility of high-resolution PET-CT imaging based on the invasive component of: * the total study population excluding DCIS (IDC + ILC + NAT); * the IDC subgroup; * the ILC subgroup; * the NAT subgroup.
Time frame: Perioperative (day 0).
Diagnostic performance based on any margin of breast cancer.
Sensitivity, specificity, positive and negative predictive value, failure rate and, interobserver reproducibility of high-resolution PET-CT imaging based on any margin of: * the total study population (IDC + DCIS + ILC + NAT); * the IDC subgroup; * the DCIS subgroup; * the ILC subgroup; * the NAT subgroup.
Time frame: Perioperative (day 0).
Reoperation rate.
The number of patients that require a second or a third surgery due to positive margins at initial primary breast-conserving surgery and the type of repeat surgery (BCS or mastectomy).
Time frame: Follow-up visit (+/- week 2).
Resected tissue volume.
The volume (mm³) of resected main specimen, and possible cavity shaves after PET-CT imaging and possible cavity shaves after standard-of-care approach.
Time frame: Perioperative (day 0).
Detection of malignant cells in cavity shaves and resected lymph nodes.
A measure of success in detecting malignant cells in resected lymph nodes and cavity shaves with the adjunctive use of high-resolution PET-CT specimen imaging as detected by permanent pathology.
Time frame: Perioperative (day 0).
Ran from Jun 2022 to primary completion in Mar 2025, 33 months.
Of 110 industry-sponsored interventional studies with no phase under Breast Neoplasms, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 59. This study's 33 months is above that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.